BridgeMD
The GOBLET trial: A clinical trial on GOblet cell density after Benzalkonium chloride and preservative-free Latanoprost Eye drop Treatment
EU CTIS ID: 2024-512275-12-00
What this study is testing
To compare goblet cell density when treating with a BAK-preserved and preservative-free latanoprost eye drops
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- age ≥18 years
- IOP ≥ 22 mmHg on each eye measured by an opthalmologist
- OHT or POAG
- danish speaking
You likely can't join if
- History with significnat treatment required eye disease (including trauma) other than POAG or OHT
- Need for multidrug glaucoma treatment
- Ocular surface disease based on fluorescein staining at inklusion
- Women not using safe contraception. The following contraception is accepted and shall be used under the entire study period: IUD or hormonal contraception (pill, implant, transdermal bandaid, vaginal ring or injektion). Sterile and non-fertile women do not need to use contraception. To be considered non-fertile or sterile a woman must be sterilized through surgery (Bilateral Tubal Ligation, hysterectomy or bilateral ovariectomy) or be postmenopausal (defined as at least 12 months since last period before inklusion). After completing the study there will be no need to follow up on fertile women regarding potential pregnancy as the study medication has poor systemic absorption and does not have a teratogen effect.
- Pregnant or nursing. Pregnancy test will be performed on fertile women at inklusion
- Treatment with systemic or lokal steroid within 3 months of study start g. Significant untreated systemic disease such as hypertension, heart failure, diabetes mellitus, stroke, lung disease and autoimmune disease. Diseases are acceptable if well-treated or if no treatment is required.
See the full eligibility criteria
- age ≥18 years
- IOP ≥ 22 mmHg on each eye measured by an opthalmologist
- OHT or POAG
- danish speaking
- History with significnat treatment required eye disease (including trauma) other than POAG or OHT
- Need for multidrug glaucoma treatment
- Ocular surface disease based on fluorescein staining at inklusion
- Women not using safe contraception. The following contraception is accepted and shall be used under the entire study period: IUD or hormonal contraception (pill, implant, transdermal bandaid, vaginal ring or injektion). Sterile and non-fertile women do not need to use contraception. To be considered non-fertile or sterile a woman must be sterilized through surgery (Bilateral Tubal Ligation, hysterectomy or bilateral ovariectomy) or be postmenopausal (defined as at least 12 months since last period before inklusion). After completing the study there will be no need to follow up on fertile women regarding potential pregnancy as the study medication has poor systemic absorption and does not have a teratogen effect.
- Pregnant or nursing. Pregnancy test will be performed on fertile women at inklusion
- Treatment with systemic or lokal steroid within 3 months of study start g. Significant untreated systemic disease such as hypertension, heart failure, diabetes mellitus, stroke, lung disease and autoimmune disease. Diseases are acceptable if well-treated or if no treatment is required.
- Known allergy towards active drug or additives in study medication.
- Patients unable to coorperate
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.